Treatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis

Background: A consensus is lacking on optimal treatment sequencing for follicular lymphoma (FL), the most common indolent lymphoma. FL incurable, and many patients require multiple lines of therapy successive relapses. Guidelines provide numerous recommendations first-, second-, third-line therapy; however, patterns in real world remain poorly understood. Objectives: The primary objective this study to evaluate real-world among commercially insured with United States. Methods: retrospective cohort newly diagnosed was identified from June 2008 September 2016 using IBM MarketScan® database. Treatment pattern measures, including time diagnosis, days previous line therapy, duration distribution regimens were assessed. Descriptive statistics reported baseline characteristics, outcome, measures. Results: In total, 4232 database 2111 received at least 1 treatment. first-line treatments included bendamustine + rituximab (39%), cyclophosphamide doxorubicin vincristine (20%), monotherapy (19%). Rituximab second-line (34%) third or greater (57%) median diagnosis initiation 50 (interquartile range [IQR]: 28-191) treatment, 577 (IQR: 312-1146) second-line, 776 603-1290) third-line. Discussion: At a follow-up 3.6 years, had fewer therapy. use combination decreased each numbers receiving third- fourth-line small study, potentially due short follow-up. as utilized frequently; variety other therapies used demonstrates that standard management remains unclear. Conclusions: Consensus currently lacking, receive active during routine practice. contemporary States, predominated both combination.